Key Factors
Pfizer’s inventory has skilled a major decline of over 50% from its pandemic peak.
Regardless of challenges, Pfizer’s newest earnings report revealed resilience, topping estimates with an sudden fourth-quarter revenue.
Analysts forecast a formidable upside for Pfizer, with a consensus worth goal of $36.93, and the inventory boasts a pretty dividend yield of 6.11%.
5 shares we like higher than Pfizer
For shareholders of the multinational biotech big Pfizer Inc. NYSE: PFE, it’d really feel just like the inventory’s all-time highs set in the course of the pandemic have been centuries in the past. After making its COVID-19-related all-time excessive in late 2021, the inventory turned decrease and has since been in a steep downtrend, declining by greater than 50% from the 2021 excessive.
The regular decline performed out because the world emerged from the pandemic, and several other biotech firms grappled with the lowering demand for his or her COVID-related merchandise. Nonetheless, in its newest earnings report, the corporate reported an earnings beat as its declining COVID enterprise misplaced lower than anticipated.
So the query now beckons: May this steep, regular selloff current a possibility to select up shares of PFE on a budget as its inventory approaches 10-year assist close to $26?
Pfizer tops estimates, navigates headwinds
Pfizer delivered an sudden fourth-quarter revenue regardless of a dip in COVID-19-related income, showcasing resilience amid shifting market dynamics. The return of fewer Paxlovid doses than initially estimated was a notable issue contributing to this stunning end result, indicating a possible uptick in Paxlovid utilization. 
Though income from Pfizer’s COVID-19 vaccine decreased by 53% in comparison with the earlier 12 months, it nonetheless generated $5.36 billion in gross sales, surpassing analysts’ expectations of $4.99 billion.
Pfizer noticed encouraging progress in its product portfolio. Income from its RSV vaccine, Abrysvo, reached $515 million for the quarter, whereas medication like Vyndaqel and Eliquis carried out nicely, with gross sales figures of $961 million and $1.61 billion, respectively. Nonetheless, gross sales of pneumococcal pneumonia pictures fell in need of expectations at $1.60 billion, indicating challenges in that section.Regardless of these blended outcomes, Pfizer’s total income for the fourth quarter stood at $14.25 billion, down 41% from final 12 months. Adjusted earnings per share for the quarter have been 10 cents, surpassing analysts’ expectations of a lack of 22 cents per share. Nonetheless, the decline in COVID-19 product gross sales was vital, with income from Pfizer’s COVID-19 vaccine and Paxlovid dropping by 78% from their peak in 2022 to $12.5 billion in 2023.
Amidst these challenges, Pfizer’s acquisition of Seagen for $43 billion within the fourth quarter goals to revitalize investor confidence. The merger ought to double Pfizer’s oncology analysis capabilities and bolster its income progress. Nonetheless, with Pfizer’s inventory already down over 4% year-to-date and skepticism lingering about its potential to navigate market headwinds, the corporate faces a crucial juncture in its efforts to maintain progress and innovation.
Lofty worth goal and engaging dividend
Whereas the inventory has a “maintain” score, a score it has held for over a 12 months, its present worth goal forecasts a formidable upside. Primarily based on fifteen analyst scores, PFE has a consensus worth goal of $36.93, forecasting a 34% upside. Most just lately, analysts at Cantor Fitzgerald reiterated its score on PFE and a worth goal of $45, which sees an upside of over 64% for the inventory.
The inventory provides a major dividend yield of 6.11% and a pretty worth goal. Pfizer has a 12.89% annualized three-year dividend progress and a fourteen-year dividend improve monitor file. Its subsequent dividend fee is March 1.
Bullish institutional and insider exercise

Over the earlier twelve months, complete institutional inflows have been $98.12 billion in comparison with simply $11.03 billion in outflows. Throughout the identical interval, two insiders bought inventory totaling $5.16 million. No insider gross sales occurred in the course of the interval.Earlier than you take into account Pfizer, you may need to hear this.MarketBeat retains monitor of Wall Road’s top-rated and greatest performing analysis analysts and the shares they suggest to their purchasers each day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Pfizer wasn’t on the listing.Whereas Pfizer presently has a “Maintain” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.View The 5 Shares Right here MarketBeat simply launched its listing of 10 low-cost shares which have been ignored by the market and could also be significantly undervalued. Click on the hyperlink under to see which firms made the listing.Get This Free Report